Drug Trial Radar · NCT06932068
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
77
Planned (sponsor's estimate)
Start
Mar 26, 2025
Primary completion
Oct 31, 2027
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- Qilu Hospital of Shandong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is single - arm study to explore the safety and efficacy of iparomlimab and tuvonralimab (QL1706) combined with chemotherapy for treating her2-negative, low PD-L1 expressing, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma
Conditions
- HER2 Negative
- Low PD-L1 Expressing
- Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Interventions
Iparomlimab and Tuvonralimab (QL1706)Drug
5 mg/kg, ivdrip, Day 1, Q3W, until progressive disease or intolerable toxicity.
OxaliplatinDrug
130 mg/m2, ivdrip, Day 1, Q3W, for the first 6 cycles.
Capectitabine TabletsDrug
1000 mg/m2, po, bid, Days 1-14, Q3W, until progressive disease or intolerable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression-free survival (PFS)Time frame: 12 months after the last subject participating in
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Jining First People's Hospital
Jining, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Binzhou Medical University Hospital
Binzhou, Shandong, China · Recruiting
Dezhou People's Hospital
Dezhou, Shandong, China · Recruiting
Shengli Oilfield Central Hospital
Dongying, Shandong, China · Recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China · Recruiting
Shandong Provincial Third Hospital
Jinan, Shandong, China · Recruiting
Jinan Central Hospital
Jinan, Shandong, China · Recruiting
Jinan Third People's Hospital
Jinan, Shandong, China · Recruiting
Shandong Qianfoshan Hospital
Jinan, Shandong, China · Recruiting
Affiliated Hospital of Jining Medical College
Jining, Shandong, China · Recruiting
Liaocheng People's Hospital
Liaocheng, Shandong, China · Recruiting
Linyi Cancer Hospital
Linyi, Shandong, China · Recruiting
Linyi People's Hospital
Linyi, Shandong, China · Recruiting
Qilu Hospital of Shandong University(Qingdao)
Qingdao, Shandong, China · Recruiting
Qingdao Municipal Hospital
Qingdao, Shandong, China · Recruiting
Qingdao Municipal Hospital
Qingdao, Shandong, China · Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
Taian City Central Hospital
Tai’an, Shandong, China · Recruiting
The Second Affiliated Hospital of Shandong First Medical University
Tai’an, Shandong, China · Recruiting
Tengzhou Central People's Hospital
Tengzhou, Shandong, China · Recruiting
Weifang Hospital of Traditional Chinese Medicine
Weifang, Shandong, China · Recruiting
Weihai Central Hospital
Weihai, Shandong, China · Recruiting
Yantai Yuhuangding Hospital
Yantai, Shandong, China · Recruiting
Yantai Yuhuangding Hospital
Yantai, Shandong, China · Recruiting
Yantaishan Hospital
Yantai, Shandong, China · Recruiting
Zibo Central Hospital
Zibo, Shandong, China · Recruiting
Zibo First People's Hospital
Zibo, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.